Table 2

CGRP inhibitor response rates in major preventative trials

SubjectsDoseMean migraine Days50% responder rate75% responder rate100% responder rate
Active
(Δ days)
Placebo
(Δ days)
Active
(%)
Placebo
(%)
Active
(%)
Placebo
(%)
Active
(%)
Placebo (%)
Atogepant
EM (phase IIb/III)
NCT02848326(s9)
83460 mg two times per day−4.14−2.8540.462.1
Eptinezumab
EM (phase II)
NCT01772524(s64)
1741000 mg−5.6−4.66133339160
EM (phase III)
NCT02559895(s65)
888300 mg Q3/12−4.3−3.256.337.431.520.3
CM (phase III)
NCT02974153(s20),(s66)
1072300 mg Q3/12−8.8−6.163.444.542.322.7
Erenumab
EM (phase II)
NCT01952574(s67)
48370 mg Q1/12−3.4−2.34630
EM (phase III)
NCT02456740(s63)
95570 mg Q1/12−3.2−1.843.326.6
140 mg Q1/12−3.7−1.85026.6
EM with 2–4 treatment failure (phase IIIb) NCT03096834(s21)246140 mg Q1/12−1.8−0.2301412460
CM (phase II)
NCT02066415(s22)
66770 mg Q1/12−6.6−4.24023
140 mg Q1/12−6.6−4.24123
CM with MOH
(subgroup)(s24)
274140 mg Q1/12−6.6. 3.534.617.7
CM with ≥2 treatment failure
(subgroup)(s23)
327140 mg Q1/12−7.0−2.741.314.221.73.5
Fremanezumab
EM (phase IIb)
NCT02025556(s25)
297675 mg Q1/12−5.55−2.8953283411
EM (phase III)
NCT02629861(s26)
875225 mg Q1/12−3.7−2.247.727.9
675 mg Q3/12−3.4−2.244.427.9
EM/CM ≥2 prev. treatment
(phase IIIb)
NCT03308968(s27)
838225 mg Q1/12−4.1−0.634912210
675 mg Q3/12−3.7−0.63498200
CM (phase III)
NCT02621931(s28)
1130225 mg Q1/12−5.0−3.24118
675 mg Q3/12−4.9−3.23818
Galcanezumab
EM (phase II)
NCT01625988(s68)
218150 mg Q2/52−4.2−3.0704549273217
EM (phase III)
NCT02614196(s29)
915120 mg
Q1/12
−4.3−2.359.33633.517.811.55.7
240 mg Q1/12−4.2−2.356.53634.317.813.85.7
EM (6-month extension)(s69)1773120 mg
Q1/12
6.21.80.70.2
240 mg Q1/126.81.81.40.2
CM (phase III)
NCT02614261(s30)
1113120 mg
Q1/12
−4.8−2.727.615.47.04.50.70.5
240 mg Q1/12−4.6−2.727.515.48.84.51.30.5
CM ≥1 treatment failures
NCT02614261(s70)
573120 mg
Q1/12
−5.35−1.0129.69.46.32.3
240 mg Q1/12−2.77−1.0118.79.45.02.3
  • CM, chronic migraine; EM, episodic migraine; MOH, medication overuse headache.